EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effect of 100 mg of testosterone cypionate in trans men with erythrocytosis: a randomized controlled pilot study

Sérgio Henrique Pires Okano iD, Silvio Antônio Franceschini, Débora Aiesha Leite Cantelli, Ana Carolina Japur de Sá Rosa E Silva, Rui Alberto Ferriani, Luiz Gustavo Oliveira Brito, Lúcia Alves da Silva Lara

The Journal of Sexual Medicine · 2025

DOI: 10.1093/jsxmed/qdaf263 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Sérgio Henrique Pires Okano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, PC 14040-900, Brazil. Hauptthemen laut MEDLINE: Testosterone, Polycythemia, Transgender Persons, Androgens. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Testosterone cypionate is commonly administered at 200 mg every 2 weeks to facilitate masculinization in transgender men. However, this regimen may increase hematocrit (Hct) by up to 6.9%.

Aim

To compare the effects of biweekly intramuscular administration of 100 mg testosterone cypionate versus testosterone suspension on hematologic parameters and testosterone concentration in transgender men with erythrocytosis.

Methods

A randomized, controlled pilot clinical trial which enrolled transgender men aged 18-40 years with secondary erythrocytosis (Hct ≥ 50%) related to testosterone therapy. Exclusion criteria included current contraceptive use, severe psychiatric disorders, or Hct ≥ 55%. Participants received either biweekly supervised intramuscular injections of 100 mg testosterone cypionate for 3 months or underwent complete testosterone withdrawal. Main Outcome Measures Hct, hemoglobin, and total testosterone concentrations.

Results

Forty-three participants completed the study protocol. Greater reductions in Hct were observed in the control group (−3.5 ± 0.5% vs −0.8 ± 0.5%; P < .001), as well as in hemoglobin (−0.97 ± 0.16 g/dL vs −0.17 ± 0.17 g/dL; P = .002) and testosterone (−510.16 ± 120.42 ng/dL vs 75.72 ± 123.26 ng/dL; P = .002). However, this difference was significant only when a >1.0 percentage point reduction in Hct was expected. In the intervention group, reductions in diastolic blood pressure (117.05 ± 13.72 mmHg vs 113.19 ± 12.77 mmHg; P = .040), body weight (70.59 ± 15.16 kg vs 69.34 ± 14.44 kg; P = .003), and HADS anxiety scores (7.90 ± 4.37 vs 5.19 ± 4.17; P = 0.001) were also observed. No serious adverse events were reported. Clinical Implications Dose reduction, although less effective than complete testosterone suspension in lowering Hct, suggests a potentially valuable strategy for patients with moderately elevated Hct levels. In this group, Hct levels remained stable and within acceptable limits, while therapeutic serum testosterone concentrations were preserved. Strengths and Limitations To our knowledge, this is the first clinical trial to assess the impact of testosterone dose fractionation in transgender men, with close monitoring and follow-up in both intervention arms. Among the study’s limitations are the absence of a sham control group and the use of a convenience sample recruited from a single specialized center.

Conclusion

Testosterone suspension appears to be more effective in reducing Hct than dose reduction when a decrease greater than 1% in Hct is desired. Nonetheless, dose reduction preserved therapeutic testosterone levels while offering additional benefits in blood pressure, anxiety, and body weight.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TestosteronePolycythemiaTransgender PersonsAndrogensHumansMalePilot ProjectsAdultYoung AdultHematocritAdolescentInjections, IntramuscularHemoglobins

Stichwörter der Autor:innen

drug therapyhematocritpolycythemiatestosteronetransgender persons

Substanzen

Testosteronetestosterone 17 beta-cypionateHemoglobinsAndrogens

Autor:innen und Institutionen

  • Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, PC 14040-900, Brazil.
  • State Faculty of Medical Sciences, State University of Campinas, Campinas, PC 13083-887, Brazil.

ORCID-Profile: Sérgio Henrique Pires Okano

Zitieren

APA

Okano, S. H. P., Franceschini, S. A., Cantelli, D. A. L., de Sá Rosa E Silva, A. C. J., Ferriani, R. A., Brito, L. G. O., & da Silva Lara, L. A. (2025). Effect of 100 mg of testosterone cypionate in trans men with erythrocytosis: a randomized controlled pilot study. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf263

Vancouver

Okano SHP, Franceschini SA, Cantelli DAL, de Sá Rosa E Silva ACJ, Ferriani RA, Brito LGO, et al. Effect of 100 mg of testosterone cypionate in trans men with erythrocytosis: a randomized controlled pilot study. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf263

BibTeX
@article{Okano2025,
  author = {Okano, Sérgio Henrique Pires and Franceschini, Silvio Antônio and Cantelli, Débora Aiesha Leite and de Sá Rosa E Silva, Ana Carolina Japur and Ferriani, Rui Alberto and Brito, Luiz Gustavo Oliveira and da Silva Lara, Lúcia Alves},
  title = {Effect of 100 mg of testosterone cypionate in trans men with erythrocytosis: a randomized controlled pilot study},
  journal = {The Journal of Sexual Medicine},
  year = {2025},
  doi = {10.1093/jsxmed/qdaf263}
}
Kostenlos starten →